Találati lista | Tudóstér

001-es BibID:	BIBFORM077350
035-os BibID:	(WoS)000442465300008 (Scopus)85047308664
Első szerző:	Ludvigsson, Jonas F.
Cím:	Outcome measures in coeliac disease trials : the Tampere recommendations / Jonas F. Ludvigsson, Carolina Ciacci, Peter H. R. Green, Katri Kaukinen, Ilma R. Korponay-Szabo, Kalle Kurppa, Joseph A. Murray, Knut Erik Aslaksen Lundin, Markku J. Maki, Alina Popp, Norelle R. Reilly, Alfonso Rodriguez-Herrera, David S. Sanders, Detlef Schuppan, Sarah Sleet, Juha Taavela, Kristin Voorhees, Marjorie M. Walker, Daniel A. Leffler
Dátum:	2018
ISSN:	0017-5749
Megjegyzések:	Objective A gluten-free diet is the only treatment option of coeliac disease, but recently an increasing number of trials have begun to explore alternative treatment strategies. We aimed to review the literature on coeliac disease therapeutic trials and issue recommendations for outcome measures. Design Based on a literature review of 10 062 references, we (17 researchers and 2 patient representatives from 10 countries) reviewed the use and suitability of both clinical and non-clinical outcome measures. We then made expert-based recommendations for use of these outcomes in coeliac disease trials and identified areas where research is needed. Results We comment on the use of histology, serology, clinical outcome assessment (including patient-reported outcomes), quality of life and immunological tools including gluten immunogenic peptides for trials in coeliac disease. Conclusion C areful evaluation and reporting of outcome measures will increase transparency and comparability of coeliac disease therapeutic trials, and will benefit patients, healthcare and the pharmaceutical industry.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Gut. - 67 : 8 (2018), p. 1410-1424. -
További szerzők:	Ciacci, Carolina Green, Peter H. R. Kaukinen, Katri Korponay-Szabó Ilma (1959-) (gyermekgyógyász) Kurppa, Kalle Murray, Joseph A. Lundin, Knut Erik Aslaksen Mäki, Markku Popp, Alina Reilly, Norelle R. Rodriguez-Herrera, Alfonso Sanders, David S. Schuppan, Detlef Sleet, Sarah Taavela, Juha Voorhees, Kristin Walker, Marjorie M. Leffler, Daniel A.
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM048569
Első szerző:	Romanos, Jihane
Cím:	Improving coeliac disease risk prediction by testing non-HLA variants additional to HLA variants / Jihane Romanos, Anna Rosén, Vinod Kumar, Gosia Trynka, Lude Franke, Agata Szperl, Javier Gutierrez-Achury, Cleo C. van Diemen, Roan Kanninga, Soesma A. Jankipersadsing, Andrea Steck, Georges Eisenbarth, David A. van Heel, Bozena Cukrowska, Valentina Bruno, Maria Cristina Mazzilli, Concepcion Núñez, Jose Ramon Bilbao, M. Luisa Mearin, Donatella Barisani, Marian Rewers, Jill M. Norris, Anneli Ivarsson, H. Marieke Boezen, Edwin Liu, Cisca Wijmenga, PreventCD Group
Dátum:	2014
ISSN:	0017-5749
Megjegyzések:	BACKGROUND:The majority of coeliac disease (CD) patients are not being properly diagnosed and therefore remain untreated, leading to a greater risk of developing CD-associated complications. The major genetic risk heterodimer, HLA-DQ2 and DQ8, is already used clinically to help exclude disease. However, approximately 40% of the population carry these alleles and the majority never develop CD.OBJECTIVE:We explored whether CD risk prediction can be improved by adding non-HLA-susceptible variants to common HLA testing.DESIGN:We developed an average weighted genetic risk score with 10, 26 and 57 single nucleotide polymorphisms (SNP) in 2675 cases and 2815 controls and assessed the improvement in risk prediction provided by the non-HLA SNP. Moreover, we assessed the transferability of the genetic risk model with 26 non-HLA variants to a nested case-control population (n=1709) and a prospective cohort (n=1245) and then tested how well this model predicted CD outcome for 985 independent individuals.RESULTS:Adding 57 non-HLA variants to HLA testing showed a statistically significant improvement compared to scores from models based on HLA only, HLA plus 10 SNP and HLA plus 26 SNP. With 57 non-HLA variants, the area under the receiver operator characteristic curve reached 0.854 compared to 0.823 for HLA only, and 11.1% of individuals were reclassified to a more accurate risk group. We show that the risk model with HLA plus 26 SNP is useful in independent populations.CONCLUSIONS:Predicting risk with 57 additional non-HLA variants improved the identification of potential CD patients. This demonstrates a possible role for combined HLA and non-HLA genetic testing in diagnostic work for CD.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Gut 63 : 3 (2014), p. 415-422. -
További szerzők:	Rosen, Anna Kumar, Vinod Trynka, Gosia Franke, Lude Szperl, Agata Gutierrez-Achury, Javier van Diemen, Cleo C. Kanninga, Roan Jankipersadsing, Soesma A. Steck, Andrea Eisenbarth, Georges Heel, David A., van Cukrowska, Bozena Bruno, Valentina Mazzilli, Maria Cristina Núnez, Concepción Bilbao, Jose Ramon Mearin, Maria Luisa Barisani, Donatella Rewers, Marian Norris, Jill M. Ivarsson, Anneli Boezen, H. Marieke Liu, Edwin Wijmenga, Cisca Korponay-Szabó Ilma (1959-) (gyermekgyógyász) PreventCD Group
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: